HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Deals

Why AI maker Anthropic’s deal with Coefficient Bio could be a pharma turning point

The large AI player is paying $400 million for the tiny startup, signaling a potential shift in how tech is approaching opportunities in drug development.

By PharmaVoice · Apr 28, 2026 · via PharmaVoice
Why AI maker Anthropic’s deal with Coefficient Bio could be a pharma turning point

Image: PharmaVoice

This is an aggregated industry headline. Read the full story at PharmaVoice →

Tags
dealsformat:headlineheadlinePharmaVoice
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
Sun Pharma strikes biopharma's largest deal of '26 with $11.75B buyout of Organon
DealsFiercePharma ↗
Sun Pharma strikes biopharma's largest deal of '26 with $11.75B buyout of Organon
Already the largest biopharma company in India, generics powerhouse Sun Pharma has doubled in size with its ac…
Apr 28, 2026
Merck’s new AI commercial strategy ‘reimagining engagement with HCPs’
DealsFiercePharma ↗
Merck’s new AI commercial strategy ‘reimagining engagement with HCPs’
Merck & Co.’s $1 billion deal with Google Cloud is seeking to bolster its AI credentials—and the U.S. Big …
Apr 27, 2026
McKesson swaps minority stake in surgical unit to Apollo Funds for $1.25B
DealsFierceBiotech ↗
McKesson swaps minority stake in surgical unit to Apollo Funds for $1.25B
McKesson has let go of a minority share of its medical/surgical solutions division for $1.25 billion to Apollo…
Apr 27, 2026